Visual and safety outcomes in 300 subjects with age-related macular degeneration undergoing cataract or clear lens extraction and iolAMD Eyemax extended macular vision intraocular lens implantation

Session Details

Session Title: Pseudophakic IOLs: Monofocal

Session Date/Time: Monday 09/10/2017 | 16:30-18:00

Paper Time: 16:30

Venue: Room 2.1

First Author: : B.Qureshi UK

Co Author(s): :    S. Robbie                    

Abstract Details

Purpose:

To determine the effect of implantation of the iolAMD eyemax mono (Eyemax; London Eye Hospital Pharma) extended macular vision intraocular lens on corrected distance and corrected near visual acuity in a cohort of subjects with age-related macular degeneration.

Setting:

London Eye Hospital, 4 Harley St, London UK

Methods:

Retrospective study of 300 eyes with mild-to-severe visual loss secondary to age-related macular degeneration undergoing femtosecond laser assisted cataract surgery and implantation with the iolAMD Eyemax extended macular vision intraocular lens (IOL). The Eyemax lens is a single-piece, injectable, hydrophobic acrylic IOL positioned in the capsular bag and designed to optimise retinal image quality at up to 8 degrees from the foveal centre in subjects with macular pathology. Corrected distance (CDVA; LogMAR) and corrected near acuity (N-point; LogMAR conversion) were assessed baseline and >1 month post-implantation.

Results:

Mean age at surgery was 80 years (range 43 – 94); mean duration of follow-up was 2.5 months (range 1 – 16 months). Safety outcomes were comparable to those of standard monofocal IOLs (two cases of post-operative ocular hypertension and one of post-operative cystoid macular oedema). Mean pre-operative CDVA was 1.02; mean post-operative CDVA was 0.67, equating to an approximate ETDRS gain of 17 letters. Mean pre-operative CDVA was 1.37 increasing to 0.88, an approximate ETDRS gain of 25 letters.

Conclusions:

The iolAMD Eyemax extended macular vision IOL has a safety profile comparable with standard monofocal IOLs. We found significant improvements in CDVA and CNVA post-implantation in patients with intermediate to advanced dry AMD far exceeding improvements achieved with antiVegF treatments (ETDRS gain of 7 letters) for wet AMD. Evidence suggests that subjects with AMD implanted with standard monofocal IOLs during cataract surgery can expect a gain of 6.5 – 7.5 ETDRS letters compared with the approximate ETDRS letter gain of 17-25 letters in those implanted with the iolAMD Eyemax IOL in this cohort.

Financial Disclosure:

gains financially from product or procedure presented